Latest Articles
No checkpoint glory for Acrivon | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
No checkpoint glory for Acrivon | ApexOnco - Clinical Trials news and analysis Oncology Pipeline
Published: Jan. 12, 2026, 1:11 p.m.
Abdominal wall endometriosis in a caesarean section scar.
A woman in her 30s with a history of three caesarean sections was referred to gynaecology oncology for evaluation of abnormal uterine bleeding and a painful anterior abdominal wall mass …
Published: Jan. 12, 2026, midnight
Novel Small Molecule Inhibitors Show Efficacy in Endometrial Cancer - Targeted Oncology
Novel Small Molecule Inhibitors Show Efficacy in Endometrial Cancer Targeted Oncology
Published: Jan. 11, 2026, 4:14 p.m.
AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty - ETPharma.com
AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty ETPharma.com
Published: Jan. 10, 2026, 1:55 a.m.
AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty - ET Pharma
AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty ET Pharma
Published: Jan. 10, 2026, 1:55 a.m.
Using Lenvatinib/Pembrolizumab for Endometrial Cancer in Clinical Practice - Targeted Oncology
Using Lenvatinib/Pembrolizumab for Endometrial Cancer in Clinical Practice Targeted Oncology
Published: Jan. 5, 2026, 1:27 p.m.
Real-World Results for Lenvatinib Plus Pembrolizumab in Endometrial Cancer - Targeted Oncology
Real-World Results for Lenvatinib Plus Pembrolizumab in Endometrial Cancer Targeted Oncology
Published: Jan. 5, 2026, 1:12 p.m.
Lenvatinib Plus Pembrolizumab in Endometrial Cancer After Neoadjuvant/Adjuvant Therapy - Targeted Oncology
Lenvatinib Plus Pembrolizumab in Endometrial Cancer After Neoadjuvant/Adjuvant Therapy Targeted Oncology
Published: Jan. 5, 2026, 1:07 p.m.
Phase 3 Trial of T-DXd Initiated in HER2+ Endometrial Cancer - Targeted Oncology
Phase 3 Trial of T-DXd Initiated in HER2+ Endometrial Cancer Targeted Oncology
Published: Dec. 23, 2025, 2:07 p.m.
Safety and Optimal AE Management of Lenvatinib Plus Pembrolizumab in Endometrial Cancer - Targeted Oncology
Safety and Optimal AE Management of Lenvatinib Plus Pembrolizumab in Endometrial Cancer Targeted Oncology
Published: Dec. 22, 2025, 1:15 p.m.
Link copied to clipboard!